spdb

SPDB 是一种可降解的 ADC 连接剂，可用于合成抗体偶联药物。SPDB是一个与 DM4 偶联物相连的小片段并利用二硫键与抗体偶联。

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

SPDB-sulfo, a glutathione-cleavable linker, is utilized in the development of antibody-drug conjugates (ADCs) [1].

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

sulfo-SPDB is a cleavable linker vital in ADC synthesis. sulfo-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

SPDB-DM4 是 ADC 的一部分，由 DM1 (一种微管蛋白抑制剂，也是一种抗体可缀合的美登木素生物碱，用于克服与美登素相关的全身毒性并增强肿瘤特异性递送) 和 SPDB 连接而成，具有高效的抗肿瘤活性。

Lys-Nε-SPDB-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC).

NO2-SPDB-sulfo is a cleavable linker vital in ADC synthesis. NO2-SPDB-sulfo joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

DMAC-SPDB is a cleavable linker vital in ADC synthesis. DMAC-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

DMAC-SPDB-sulfo is a cleavable linker vital in ADC synthesis. DMAC-SPDB-sulfo joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

Sulfo-SPDB-DGN462为一种ADC活性连接剂，毒素DGN462通过可裂解的Sulfo-SPDB linker偶联形成。DGN462是一种DNA烷基化剂，对抗肿瘤（如急性髓系白血病[AML]）表现出有效性。

Dimethylamine-SPDB是一种可降解 (cleavable) 的ADC linker，用于合成抗体偶联活性分子 (ADC)。

Anti-CCL2 (Carlumab)-SPDB-DM4 是一种抗体-药物偶联物 (ADC)，由人源性抗CCL2 (趋化因子配体 2) 抗体 Carlumab 通过连接子 SPDB 和微管蛋白 (tubulin) 抑制剂 DM4 连接而成。其毒性分子和连接体部分为 sulfo-SPDB-DM4，可用于癌症研究。

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 是一种抗体-药物偶联物 (ADC)，由人源抗SLC34A2(钠依赖性磷酸转运蛋白 2) 的抗体 Lifastuzumab 与连接子 SPDB 以及微管蛋白 (tubulin) 抑制剂 DM4 结合而成。其 ADC 的毒性分子和连接子部分为 sulfo-SPDB-DM4。Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 适用于癌症研究。

Tusamitamab ravtansine (SAR-408701) 是一款针对CEACAM5的人源化单克隆抗体与DM4细胞毒性药物经活性分子连接而成的抗体-药物偶联物(ADC)，专门靶向CEACAM5表达的肿瘤细胞。

ADC Control Human IgG1-DM4 作为 ADC Human IgG1-DM4 的同型对照，具体结构包括 HumanIgG1kappa (Isotype Control) 作为抗体部分，而其毒性分子和 linker 配置为 SPDB-DM4。